Skip to content

Trial Summary

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Acronym:

BAY 88- 8223/20510

ACTRN/NCT /ethics:

NCT04597125

Scientific title:

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel antihormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.

Sponsor / Cooperative group:

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase IV
Age Range18 years and older
SexMale
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2020-11-09
Anticipated End Date2024-12-10

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorProfessor Hsiang Tan
Recruitment StatusNot Yet Recruiting